Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    198 result(s) found for: Histamine. Displaying page 8 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2012-003995-38 Sponsor Protocol Number: CQAW039A2214 Start Date*: 2013-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 (450 mg QD) on FEV1 and ACQ in non-atopic, asthmatic patients with a baseline, pre-bronchodilator FEV1 o...
    Medical condition: Moderate-to-severe, persistent asthma, inadequately controlled with ICS therapy.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-004622-81 Sponsor Protocol Number: NN1998-1616 Start Date*: 2007-11-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: a 52-week, open-label, multinational, randomised, parallel tr...
    Medical condition: Type 1 diabetes Type 2 diabetes Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10045242 Type II diabetes mellitus LLT
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016968-37 Sponsor Protocol Number: IgES/CFB/2009-04 Start Date*: 2009-12-22
    Sponsor Name:Centre Francois Baclesse
    Full Title: Evaluation de l’intérêt d’un dosage des anticorps anti-cetuximab dans la prise en charge thérapeutique des patients présentant un cancer colique ou des voies aéro-digestives supérieures et candidat...
    Medical condition: Patients présentant un cancer colique ou des voies aéro-digestives supérieures et candidats à un traitement par cetuximab
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009944 Colon cancer LLT
    12.0 10009944 Colon cancer PT
    12.0 10067821 Head and neck cancer LLT
    12.0 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000984-15 Sponsor Protocol Number: PQBirch204 Start Date*: 2015-07-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: A multi-centre, double-blind, placebo-controlled study to explore the safety and efficacy of Birch Modified Allergen Tyrosine adsorbed + MPL (POLLINEX® Quattro Plus 1.0 mL Birch [PQ Birch]) in subj...
    Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016581-80 Sponsor Protocol Number: HZA113090 Start Date*: 2010-01-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005615-21 Sponsor Protocol Number: 205.341 Start Date*: 2006-07-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Ti...
    Medical condition: Patients with severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002317-34 Sponsor Protocol Number: AL2101av Start Date*: 2021-12-20
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, randomized, open label clinical trial for safety evaluation of an allergen immunotherapy with an accelerated dose escalation schedule using one strength of an aluminium hydroxide ads...
    Medical condition: moderate to severe seasonal allergic rhinitis or rhinoconjunctivitis with or w/o asthma caused by birch pollen allergens
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001883-39 Sponsor Protocol Number: P02561 Start Date*: 2004-09-21
    Sponsor Name:Schering Plough Reserach Institute
    Full Title: Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Ha...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039776 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004213-13 Sponsor Protocol Number: ST101-101 Start Date*: 2020-07-13
    Sponsor Name:Sapience Therapeutics, Inc.
    Full Title: A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
    Medical condition: Castrate-Resistant Prostate Cancer, HR Positive local advanced/metastatic Breast Cancer, Glioblastoma, and Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000900-41 Sponsor Protocol Number: WB28850 Start Date*: 2013-05-10
    Sponsor Name:F. Hoffmann-La Roche, Ltd.
    Full Title: A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA
    Medical condition: Severe corticosteroid-dependent asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003095-12 Sponsor Protocol Number: AL1303AV Start Date*: 2014-03-19
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: Double-blind phase IV multicentre clinical trial to evaluate and compare specific and non specific effects of SCIT by use of an Environmental Challenge Chamber after treatment with Allergovit® gras...
    Medical condition: Patients suffering from seasonal allergic rhinoconjunctivitis with or without controlled asthma during the birch and grass pollen season
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    17.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001938-34 Sponsor Protocol Number: 6022-PR-PRI-194 Start Date*: 2012-11-06
    Sponsor Name:Laboratorios Leti, S.L.Unipersonal
    Full Title: Biological standardization of Platanus acerifolia allergen extract to determine the biological activity in HEP units.
    Medical condition: Allergy to Platanus acerifolia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017745-55 Sponsor Protocol Number: 205.424 Start Date*: 2010-05-03
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II randomised, double-blind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25μg,...
    Medical condition: Moderate persistent asthma in adolescents (12 to 17 years old)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2009-014415-12 Sponsor Protocol Number: MEA112997 Start Date*: 2010-01-04
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled ref...
    Medical condition: severe uncontrolled refractory asthma.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001538-18 Sponsor Protocol Number: 603-PG-PSC-74 Start Date*: 2004-09-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomised, double blinded, placebo controlled multicentre study for the efficacy and safety of Depigoid birch pollen
    Medical condition: Patients have to suffer from IgE mediated allergic rhinits, rhinoconjunctivitis +/- asthma due to sensitization again birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036019 LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001931-30 Sponsor Protocol Number: 206-PG-PRI-190 Start Date*: 2012-10-18
    Sponsor Name:Laboratorios LETI, S.L.U
    Full Title: Ensayo Clínico multicéntrico, abierto, para la comparación de la potencia biológica entre los extractos alergénicos nativo, despigmentado y despigmentado-polimerizado de epitelio de gato.
    Medical condition: Alergia frente al epitelio de gato
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10001731 Allergic to cats LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000056-18 Sponsor Protocol Number: BTT-gpASIT007 Start Date*: 2013-07-15
    Sponsor Name:BioTech Tools S.A.
    Full Title: Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.
    Medical condition: Treatment of seasonal grass pollen rhinoconjunctivitis.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004870 10019170 Hay fever LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001601-85 Sponsor Protocol Number: UKM10_0037 Start Date*: 2014-02-14
    Sponsor Name:University Hospital Münster
    Full Title: Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial
    Medical condition: Patients with generalized chronic pruritus (> 6 weeks duration) and showing prurigo nodularis refractory to pretreatment with antihistamines (normal dosage, four weeks)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10037084 Prurigo nodularis LLT
    17.0 100000004858 10018123 Generalized pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022083-12 Sponsor Protocol Number: SC-11A Start Date*: 2014-05-15
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Evaluation of tolerability and efficacy of subcutaneous cluster-immunotherapy in patients with allergic rhinitis / rhino-conjunctivitis due to grass pollen
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    19.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001937-15 Sponsor Protocol Number: 6062-PR-PRI-195 Start Date*: 2012-09-28
    Sponsor Name:Laboratorios Leti, S.L.Unipersonal
    Full Title: Biological standardization of Chenopodium album allergen extract to determine the biological activity in HEP units.
    Medical condition: Allergy to Chenopodium album
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 10:24:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA